WallStSmart

Teva Pharma Industries Ltd ADR (TEVA)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 19% more annual revenue ($17.32B vs $14.56B). TEVA leads profitability with a 4.1% profit margin vs -2.0%. TEVA appears more attractively valued with a PEG of 0.96. TEVA earns a higher WallStSmart Score of 49/100 (D+).

TEVA

Hold

49

out of 100

Grade: D+

Growth: 5.3Profit: 5.5Value: 5.0Quality: 4.0
Piotroski: 6/9Altman Z: 0.28

VTRS

Hold

48

out of 100

Grade: D+

Growth: 3.3Profit: 3.5Value: 5.3Quality: 5.0
Piotroski: 4/9Altman Z: 0.55

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.968/10

Growing faster than its price suggests

VTRS1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

TEVA4 concerns · Avg: 2.5/10
Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Operating MarginProfitability
4.0%3/10

Operating margin of 4.0%

P/E RatioValuation
58.4x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-2.0%2/10

ROE of -2.0% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Profit MarginProfitability
-2.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.96 suggests the stock is reasonably priced for its growth.

Bull Case : VTRS

The strongest argument for VTRS centers on Price/Book. PEG of 1.12 suggests the stock is reasonably priced for its growth.

Bear Case : TEVA

The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 58.4x leaves little room for execution misses. Debt-to-equity of 2.05 is elevated, increasing financial risk.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

TEVA profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS carries more volatility with a beta of 0.90 — expect wider price swings.

VTRS is growing revenue faster at 8.1% — sustainability is the question.

VTRS generates stronger free cash flow (348M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (49/100 vs 48/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?